News stories about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Myriad Genetics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.8000940638164 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Top Analyst Upgrades and Downgrades: Alibaba, Blue Apron, Gap, Harmony Gold, Myriad Genetics, Noble, Walmart and More (feedproxy.google.com)
- Myriad Genetics (MYGN) vs. Vascular Solutions (VASC) Financial Survey (americanbankingnews.com)
- Myriad Genetics, Inc. (NASDAQ:MYGN) Traded 11.0% Above Its 50 Day Moving Average – Modern Readers (modernreaders.com)
- Myriad Genetics (MYGN) EndoPredict Secures Positive Coverage Decisions from Medicare & Anthem (ANTM) (streetinsider.com)
- EndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem (finance.yahoo.com)
Myriad Genetics (MYGN) traded up 3.27% during trading on Friday, reaching $28.77. 503,137 shares of the company’s stock traded hands. The company has a 50 day moving average price of $25.39 and a 200-day moving average price of $21.26. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $28.82. The company has a market cap of $1.97 billion, a PE ratio of 90.19 and a beta of 0.31.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. The firm had revenue of $200.50 million for the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the firm posted $0.36 EPS. On average, equities research analysts forecast that Myriad Genetics will post $1.02 EPS for the current fiscal year.
Several equities analysts recently issued reports on the stock. Deutsche Bank AG raised shares of Myriad Genetics from a “sell” rating to a “hold” rating and cut their price objective for the company from $27.86 to $15.00 in a report on Friday. Jefferies Group LLC reissued a “hold” rating and set a $21.00 price objective (up from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Barclays PLC cut their price objective on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.22.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.